Apimeds Pharmaceuticals US, Inc (APUS) Stock Overview
Explore Apimeds Pharmaceuticals US, Inc’s financial performance, market position, analyst ratings, and future outlook.
Apimeds Pharmaceuticals US, Inc (APUS)
Key Financials
Key Financials
Market Cap
876.5K
P/E Ratio
-0.12
EPS (TTM)
$-2.71
ROE
-0.55%
APUS Stock Analysis & Investment Overview (AMEX)
Our AI-powered analysis of Apimeds Pharmaceuticals US, Inc (AMEX: APUS) gives investors deep insight into how the stock performs on the AMEX exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Apimeds Pharmaceuticals US, Inc's AMEX-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of APUS on the AMEX shows an RSI of 38.97, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.71 for the AMEX listing.
Key metrics behind Apimeds Pharmaceuticals US, Inc's AMEX-traded stock include a P/E ratio of -0.12 and a market capitalization of 876.5K. Combined with our AI analysis, these give both institutional and retail investors a clear view of APUS on the AMEX.